Security key
097702203
Bolt Biotherapeutics, Inc. - Common Stock, $0.00001 par value (BOLT)
CUSIP: 097702203
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, $0.00001 par value
- Total 13F shares
- 887,525
- Total 13F value
- $5,096,477
- Share change
- +887,525
- SEC-reported price per share
- $5.77
- Number of holders
- 24
- Value change
- +$5,096,477
- Number of buys
- 24
- Shares outstanding
- 1,901,870
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
24
Top holders
10
BOLT full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Bolt Biotherapeutics, Inc. SEC filings
Bolt Biotherapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 097702203
Recent filing periods:
Ownership snapshot
Top reported holders of BOLT - Bolt Biotherapeutics, Inc. - Common Stock, $0.00001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
TANG CAPITAL MANAGEMENT LLC
Disclosed value leader
TANG CAPITAL MANAGEMENT LLC
Comparable rows
15/15
Latest evidence
31 Mar 2025
13F
13D/G
Lead comparable stake: 9.9%
13D/G row: TANG CAPITAL MANAGEMENT LLC
Showing 1-6 of 15 holder rows.
Quick read
TANG CAPITAL MANAGEMENT LLC leads the comparable SEC ownership view at 9.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens TANG CAPITAL MANAGEMENT LLC's linked filing trail.
Comparable ownership
Top 5
TANG CAPITAL MANAGEMENT LLC
9.9%
Vivo Capital, LLC
9.1%
Sofinnova Investments, Inc.
7.2%
Pivotal bioVenture Partners Inves...
4.9%
VANGUARD GROUP INC
3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC |
13F
13D/G
Company
|
9.9%
from 13D/G
|
$1,525,109
3,812,773 shares
|
— | 31 Mar 2025 |
| Vivo Capital, LLC |
13F
Company
|
9.1%
|
$1,408,516
3,521,291 shares
|
— | 31 Mar 2025 |
| Sofinnova Investments, Inc. |
13F
Company
|
7.2%
|
$1,101,775
2,754,437 shares
|
— | 31 Mar 2025 |
| Pivotal bioVenture Partners Investment Advisor LLC |
13F
Company
|
4.9%
|
$756,587
1,891,467 shares
|
— | 31 Mar 2025 |
| VANGUARD GROUP INC |
13F
Company
|
3%
|
$467,882
1,169,705 shares
|
— | 31 Mar 2025 |
| Nan Fung Group Holdings Ltd |
13F
Company
|
3%
|
$466,781
1,166,952 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
24
Shares
887,525
Rows available
24
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q4 2025 Across Filers
Q4 2025 holders
21
Q2 2025 holders
24
Holder diff
3
| Investor | Q4 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q4 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend